Utility of Three-Dimensional Cultures of Primary Human Hepatocytes (Spheroids) as Pharmacokinetic Models
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
This paper reviews the usefulness, current status, and potential of primary human hepatocytes (PHHs) in three-dimensional (3D) cultures, also known as spheroids, in the field of pharmacokinetics (PK). Predicting PK and toxicity means pharmaceutical research can be conducted more efficiently. Various in vitro test systems using human hepatocytes have been proposed as tools to detect hepatic toxicity at an early stage in the drug development process. However, such evaluation requires long-term, low-level exposure to the test compound, and conventional screening systems such as PHHs in planar (2D) culture, in which the cells can only survive for a few days, are unsuitable for this purpose. In contrast, spheroids consisting of PHH are reported to retain the functional characteristics of human liver for at least 35 days. Here, we introduce a fundamental PK and toxicity assessment model of PHH spheroids and describe their applications for assessing species-specific metabolism, enzyme induction, and toxicity, focusing on our own work in these areas. The studies outlined in this paper may provide important information for pharmaceutical companies to reduce termination of development of drug candidates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050 · cited 1×
“In fact, half of the drugs found to cause hepatic dysfunction during clinical trials did not produce liver damage in experimental animals [19,20].”
BackgroundEstimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018
Wouters, O. J., McKee, M., & Luyten, J. (2020) · JAMA · doi:10.1001/jama.2020.1166 · Cited by 1,531
2D and 3D Cell Cultures - a Comparison of Different Types of Cancer Cell Cultures
Kapałczyńska, M., Kolenda, T., Przybyła, W., Zajączkowska, M., Teresiak, A., Filas, V., Ibbs, M., Bliźniak, R., Łuczewski, Ł., & Lamperska, K. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.63743 · Cited by 1,499
Martignoni, M., Groothuis, G. M. M., & de Kanter, R. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.6.875 · Cited by 1,478
An analysis of the attrition of drug candidates from four major pharmaceutical companies
Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., et al. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4609 · Cited by 1,450
ACG clinical guideline: evaluation of abnormal liver chemistries
Kwo, P. Y., Cohen, S. M., & Lim, J. K. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.517 · Cited by 1,222 · cited 1×
“Clinically, AST leakage is increased in liver damage, and AST is used as a cellular injury marker [67].”
BackgroundSpheroid culture as a tool for creating 3D complex tissues
Fennema, E., Rivron, N., Rouwkema, J., van Blitterswijk, C., & de Boer, J. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2012.12.003 · Cited by 1,054 · cited 1×
“Further, cells in spheroid cultures secrete an extracellular matrix in which they reside, and they can interact with cells from their original microenvironment [31].”
BackgroundTiming of new black box warnings and withdrawals for prescription medications
Lasser, K. E. (2002) · JAMA · doi:10.1001/jama.287.17.2215 · Cited by 1,005
Bell, C. C., Hendriks, D. F. G., Moro, S. M. L., Ellis, E., Walsh, J., Renblom, A., Fredriksson Puigvert, L., Dankers, A. C. A., Jacobs, F., Snoeys, J., et al. (2016) · Scientific Reports · doi:10.1038/srep25187 · Cited by 739 · cited 3×
“4 Hepatotoxicity Metabolic activity of CYPs Proteomics Evaluation of the usefulness of spheroid cultures Ultra-low attachment plate (CORNING) Culture for 35 days after seeding [46]”
BackgroundMethod
Cited by
3D human liver spheroids for translational pharmacology and toxicology
Ingelman‐Sundberg, M., & Lauschke, V. M. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13587 · Cited by 62
Kim, M. K., Jeong, W., Jeon, S., & Kang, H.-W. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1305023 · Cited by 38
Preiss, L. C., Lauschke, V. M., Georgi, K., & Petersson, C. (2022) · The AAPS Journal · doi:10.1208/s12248-022-00689-y · Cited by 36
“Furthermore, their physiologically relevant phenotype has rendered interest for their use in drug metabolism and pharmacokinetic studies (15).”
Background
Metadata
- Authors
- Mizoi, K., Arakawa, H., Yano, K., Koyama, S., Kojima, H., & Ogihara, T.
- Venue
- Biomedicines
- Publisher
- MDPI AG
- Published
- 2020-09-23
- Volume
- 8
- Issue
- 10
- Pages
- 374
- ISSN
- 2227-9059 (ISSN-L)
- OpenAlex
- W3088368594
- Cited by
- 36
- References
- 20
- FWCI
- 3.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Utility of Three-Dimensional Cultures of Primary Human Hepatocytes (Spheroids) as Pharmacokinetic Models. https://app.cochat.ai/papers/10.3390/biomedicines8100374
- The paper
- Mizoi, K., Arakawa, H., Yano, K., Koyama, S., Kojima, H., & Ogihara, T. (2020). Utility of Three-Dimensional Cultures of Primary Human Hepatocytes (Spheroids) as Pharmacokinetic Models. Biomedicines. https://doi.org/10.3390/biomedicines8100374
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.